Key points are not available for this paper at this time.
Stillbirth affects approximately 2 million pregnancies annually and is closely linked to placental dysfunction, which may also present clinically as foetal growth restriction (FGR) or pre-eclampsia (PE). Placental dysfunction can arise from a range of insults, including the inflammatory conditions villitis of unknown aetiology (VUE) and chronic histiocytic intervillositis (CHI). Despite ample research regarding the pathophysiology of placental dysfunction, the literature surrounding placental inflammation is more limited, with no currently established treatments. In the absence of infection, placental inflammation is hypothesised to be stimulated by damage-associated molecular patterns (DAMPs), known as sterile inflammation. The NLRP3 inflammasome, a protein scaffold that unites within the cytosol of cells, is a proposed contributor. The NLRP3 inflammasome is dysregulated in numerous diseases and has shown evidence of activation through the sterile inflammatory pathway via DAMPs. Studies have demonstrated the upregulation of the NLRP3 inflammasome and its components in placentally-mediated pregnancy pathologies. However, the link between placental dysfunction seen in these disorders and the NLRP3 inflammasome is not yet firmly established. This manuscript aims to review the evidence regarding placental inflammation seen with placental dysfunction, discuss its association with the NLRP3 inflammasome, and identify potential therapeutic interventions for this pathological inflammatory response.
Moss et al. (Tue,) studied this question.